October 07, 2024

Euretina 2024: 3-Month Outcomes from VOYAGER

The presented abstract discussed global, real-world clinical and anatomical outcomes with faricimab for the treatment of nAMD and DME.

October 07, 2024

Euretina 2024: Faricimab Shows Greater Hard Exudate Reduction Compared with Aflibercept

Faricimab’s dual inhibition mechanism led to a greater reduction in HE compared to aflibercept in DME patients.

October 07, 2024

Euretina 2024: 3-Month Outcomes from VOYAGER

The presented abstract discussed global, real-world clinical and anatomical outcomes with faricimab for the treatment of nAMD and DME.

October 07, 2024

Euretina 2024: Aflibercept Showed Efficacy and Safety vs Laser Therapy in Retinopathy of Prematurity

3-Year Outcomes from FIREFLEYE next study were presented at Euretina 2024.